Skip to main content

Advertisement

SpringerLink
Log in

Does rosiglitazone adversely affect bone formation and bone mineral density in postmenopausal women?

  • Practice Point
  • Published:

From Nature Clinical Practice Endocrinology & Metabolism

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Rzonca SO et al. (2004) Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 145: 401–406

    Article  CAS  Google Scholar 

  2. Kahn SE et al. (2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355: 2427–2443

    Article  CAS  Google Scholar 

  3. Takeda Pharmaceuticals letter to healthcare providers [www.fda.gov/medwatch/safety/2007/Actosmar0807.pdf] (accessed 4 May 2007).

  4. Schwartz AV et al. (2006) Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab 91: 3349–3354

    Article  CAS  Google Scholar 

  5. Hangartner TN and Johnston CC (1990) Influence of fat on bone measurements with dual-energy absorptiometry. Bone Miner 9: 71–81

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Vicky Heath, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. AV Schwartz is an Assistant Professor in the Department of Epidemiology and Biostatistics, University of California San Francisco, CA, USA.,

    Ann V Schwartz

  2. SR Cummings is a Senior Scientist in the California Pacific Medical Center Research Institute, San Francisco, CA, USA.,

    Steven R Cummings

Authors
  1. Ann V Schwartz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Steven R Cummings
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ann V Schwartz.

Ethics declarations

Competing interests

AV Schwartz is a consultant for GlaxoSmithKline. SR Cummings declared he has no competing interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schwartz, A., Cummings, S. Does rosiglitazone adversely affect bone formation and bone mineral density in postmenopausal women?. Nat Rev Endocrinol 3, 622–623 (2007). https://doi.org/10.1038/ncpendmet0562

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpendmet0562

  • Springer Nature Limited

Search

Navigation